Awareness that the metabolic phenotype of cells within tumours is heterogeneous—and
distinct from that of their normal counterparts—is growing. In general, tumour cells …

Metabolomics is an emerging'omics' science involving the comprehensive characterization
of metabolites and metabolism in biological systems. Recent advances in metabolomics …

Summary R-2-hydroxyglutarate (R-2HG), produced at high levels by mutant isocitrate
dehydrogenase 1/2 (IDH1/2) enzymes, was reported as an oncometabolite. We show here …

Summary R-2-hydroxyglutarate (R-2HG), a metabolite produced by mutant isocitrate
dehydrogenases (IDHs), was recently reported to exhibit anti-tumor activity. However, its …

Cholangiocarcinoma (CCA) is an aggressive malignancy of the bile ducts, with poor
prognosis and limited treatment options. Here, we describe the integrated analysis of …

Abstract The oncometabolite (R)-2-hydroxyglutarate (R-2-HG) produced by isocitrate
dehydrogenase (IDH) mutations promotes gliomagenesis via DNA and histone methylation …

Age-related osteoporosis is characterized by the deterioration in bone volume and strength,
partly due to the dysfunction of bone marrow mesenchymal stromal/stem cells (MSCs) …

Altered cellular metabolism is a hallmark of gliomas. Propelled by a set of recent
technological advances, new insights into the molecular mechanisms underlying glioma …

Hotspot mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2
(IDH2) occur in a variety of myeloid malignancies and solid tumors. Mutant IDH proteins …

R-2-hydroxyglutarate accumulates to millimolar levels in cancer cells with gain-of-function
isocitrate dehydrogenase 1/2 mutations. These levels of R-2-hydroxyglutarate affect 2 …